Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, and T-cell and B-cell Immunology.
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial.
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases.
Extent and Incidence of Pseudo-Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real-World Data.
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells.
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders.
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma.
Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.
Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD.
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT.
TCR activation impairs CAR-T cytotoxicity against separate target cells
Late re-expansion and high-level persistence of CAR T-cells can be driven by single CAR+ T-cell clones without clinically evident CAR+ T-cell lymphoma
CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-up
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE.
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers.
Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production
611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors
Adoptive transfer of donor B lymphocytes: a phase 1/2a study for patients after allogeneic stem cell transplantation.
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany
Liver-FDG-uptake and CAR T-cell kinetics augment early PET/CT prognostic value for CD19-targeted CAR T-cell therapy in diffuse large B cell lymphoma
Supplementary Figure S1 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S4 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S3 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S4 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Table S1 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Supplementary Figure S3 from Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers